524 related articles for article (PubMed ID: 2527074)
1. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
4. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects.
Thomas M; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
[TBL] [Abstract][Full Text] [Related]
6. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.
Krauss AH; Woodward DF; Gibson LL; Protzman CE; Williams LS; Burk RM; Gac TS; Roof MB; Abbas F; Marshall K; Senior J
Br J Pharmacol; 1996 Mar; 117(6):1171-80. PubMed ID: 8882612
[TBL] [Abstract][Full Text] [Related]
7. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems.
Takahara K; Murray R; FitzGerald GA; Fitzgerald DJ
J Biol Chem; 1990 Apr; 265(12):6836-44. PubMed ID: 2139029
[TBL] [Abstract][Full Text] [Related]
8. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist.
Ritter JM; Doktor HS; Benjamin N; Barrow SE; Stewart-Long P
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():351-4. PubMed ID: 1825568
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic action of AA-2414 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels.
Imura Y; Terashita Z; Shibouta Y; Inada Y; Nishikawa K
Jpn J Pharmacol; 1990 Jan; 52(1):35-43. PubMed ID: 2137886
[TBL] [Abstract][Full Text] [Related]
10. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
Furci L; Fitzgerald DJ; Fitzgerald GA
J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
[TBL] [Abstract][Full Text] [Related]
13. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
15. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
16. EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade.
Jones RL; Wilson NH; Lawrence RA
Br J Pharmacol; 1989 Apr; 96(4):875-87. PubMed ID: 2743082
[TBL] [Abstract][Full Text] [Related]
17. Cinnamophilin, a novel thromboxane A2 receptor antagonist, isolated from Cinnamomum philippinense.
Yu SM; Ko FN; Wu TS; Lee JY; Teng CM
Eur J Pharmacol; 1994 Apr; 256(1):85-91. PubMed ID: 8026563
[TBL] [Abstract][Full Text] [Related]
18. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction.
Beasley RC; Featherstone RL; Church MK; Rafferty P; Varley JG; Harris A; Robinson C; Holgate ST
J Appl Physiol (1985); 1989 Apr; 66(4):1685-93. PubMed ID: 2525122
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
Krauss AH; Woodward DF; Burk RM; Gac TS; Gibson LL; Protzman CE; Abbass F; Marshall K; Senior J
J Ocul Pharmacol Ther; 1997 Aug; 13(4):303-12. PubMed ID: 9261766
[TBL] [Abstract][Full Text] [Related]
20. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
